C91.11 Chronic lymphocytic leukemia of B-cell type in remission

Name of the Condition

• Chronic lymphocytic leukemia of B-cell type in remission
• ICD-10 Code: C91.11

Summary

Chronic lymphocytic leukemia of B-cell type in remission (C91.11) is a subtype of chronic lymphocytic leukemia (CLL) where the disease is no longer detectable or active following treatment. It involves the absence of abnormal B lymphocytes in the blood, bone marrow, and lymphoid tissues, indicating a response to therapy. This condition is characterized by a lack of disease progression or symptoms, though ongoing monitoring is typically required to detect potential relapse.

Causes

The exact cause of CLL, including cases in remission, is not fully understood. It involves genetic mutations in B lymphocytes that disrupt normal cell regulation, leading to uncontrolled proliferation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. Achieving remission typically results from effective treatment, though the underlying genetic mutations may persist.

Risk Factors

• Increasing age (most common in adults over 60)
• Family history of CLL or other lymphoid cancers
• Certain genetic conditions (e.g., inherited immune disorders)
• Prior exposure to certain chemicals or radiation (less clearly established)
• Previous treatment response (relevant to remission status)

Symptoms

• No active symptoms or signs of disease (by definition of remission)
• Asymptomatic state following treatment
• Potential for residual disease detectable via sensitive testing

Diagnosis

Diagnosis of remission is confirmed through clinical evaluation and laboratory tests, including blood counts, flow cytometry, and bone marrow biopsy. These assessments verify the absence of abnormal B lymphocytes and disease activity. Imaging or other tests may be used to rule out residual or relapsed disease.

Treatment Options

Treatment for CLL in remission typically involves ongoing surveillance rather than active therapy. Options may include periodic monitoring, follow-up imaging, or additional testing to detect relapse. In some cases, maintenance therapy or clinical trials may be considered to prolong remission.

Prognosis and Follow-Up

Prognosis for CLL in remission is generally favorable, with many patients experiencing long-term disease control. Follow-up care is essential to monitor for relapse, manage potential late effects of prior treatment, and address any new symptoms. Regular appointments with a hematologist or oncologist are standard.

Complications

• Risk of relapse (disease recurrence)
• Potential for treatment-related side effects (e.g., from prior therapies)
• Long-term monitoring requirements
• Psychological impact of living with a history of cancer

Lifestyle & Prevention

• Maintain regular medical follow-up as recommended
• Adopt a healthy lifestyle to support overall well-being
• Avoid known environmental risk factors (e.g., excessive radiation exposure)
• Stay informed about symptoms that may indicate relapse

When to Seek Professional Help

Seek medical attention if new symptoms (e.g., fatigue, swollen lymph nodes, or unexplained weight loss) develop, as these may indicate relapse. Prompt evaluation is important for early intervention if disease activity returns.

Tips for Medical Coders

Document the presence of remission clearly in the medical record, including the date of remission achievement and any supporting test results. Ensure the code C91.11 is used only when remission is confirmed and active disease is absent. Verify that documentation aligns with clinical guidelines for defining remission in CLL.